Revance Therapeutics, Inc. (RVNC) Stock Price, News & Historical Data - TheStreet

Summary

Profile

Financials

Events

Ownership

Options

Symbol	Last	Change
RVNC	13.43	0.00 (0.00%)
REPL	20.76	0.00 (0.00%)
CHRS	12.59	0.00 (0.00%)
VAXX	8.16	0.00 (0.00%)
ORGO	7.31	0.00 (0.00%)

Company Info

Industry	Pharmaceuticals: Other
Sector	Health Technology
Employees	470
CEO	Mr. Mark J. Foley

Address	1222 Demonbreun Street Suite 1001, Nashville, TN 37203
Phone	1.615.724.7755
Website	www.revance.com

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Statement Summary

as of 4:00 ET PM 01/20/2022

Total Assets (MRQ)	581.8 M
Total Liabilities (MRQ)	461.7 M
Shareholders’ Equity (MRQ)	120.2 M
Total Revenue (Annual)	19.7 M
Net Income (Annual)	-74.4 M

Earnings And Estimates

as of 4:00 ET PM 01/20/2022

Current Qtr EPS Estimate	-0.88
Current FY EPS Estimate	-3.21
Long Term EPS Growth Estimate	192.00
Next Expected Earnings Date	3/2/2022

RVNC vs S&P 500

as of 01/20/2022

	Relative To S&P 500	RVNC
4 Weeks	n/a	n/a
12 Weeks	n/a	n/a
YTD	n/a	n/a

Earnings Surprises

as of 4:00 ET PM 01/20/2022

Fiscal Quarter	Estimate	Actual	Surprise
09/2021	-0.97	-0.87	-10.37%
06/2021	-0.96	-0.83	-14.06%
03/2021	-1.03	-0.86	-16.71%
12/2020	-1.18	-0.98	-16.28%
09/2020	-1.05	-1.34	+28.23%
06/2020	-0.98	-1.12	+14.60%
03/2020	-0.87	-0.82	-6.00%
12/2019	-0.95	-0.88	-7.66%

Financial Strength

as of 4:00 ET PM 01/20/2022

Pre-Tax Margin	-376.68
Net Margin	82.22
Operating Margin	-368.31
Return On Equity	-120.29
Return On Assets	-45.83
Inventory Turnover (TTM)	5.36
Sales Growth (MRQ)	119.61

Ratios

as of 4:00 PM ET 01/20/2022

Price/Earnings (TTM)	n/a
Price/Book (MRQ)	8.03
Price/Cash Flow (TTM)	0.00
Book Value (MRQ)	1.67
Quick Ratio (MRQ)	4.31
Current Ratio (MRQ)	4.46
Total Debt/Equity (MRQ)	2.71

Short Interest

as of 4:00 PM ET 01/21/2022

	% Short - 0.00%
	% Remaining Float - 100.00%

	Current	Last Month
Short Interest Date	n/a	n/a
Short Interest Shares	0	0
Short Interest Ratio	0.0	0.0

M Y M Y

Total Assets 0,0.00 0,0.00

Total Liabilities 0,0.00 0,0.00

Total Equity 0,0.00 0,0.00

M Y M Y

Total Revenue 0,0.00 0,0.00

EBT Exc.
Unusual Items 0,0.00 0,0.00

Net Income 0,0.00 0,0.00

M Y M Y

Cash from
Operations 0,0.00 0,0.00

Cash from
Activities 0,0.00 0,0.00

Cash from
Fin. Activities 0,0.00 0,0.00

Select Period

TOTAL ASSETS	TOTAL LIABILITIES	TOTAL EQUITY

Balance Sheet

	M Y
ASSETS
Cash And Equivalents	0,0.00
Receivables	0,0.00
Inventories	0,0.00
Other Current Assets	0,0.00
Total Current Assets	0,0.00
Property, Plant & Equipment, Gross	0,0.00
Accumulated Depreciation & Depletion	0,0.00
Property, Plant & Equipment, Net	0,0.00
Intangibles	0,0.00
Other Non-Current Assets	0,0.00
Total Non-Current Assets	0,0.00
TOTAL ASSETS	0,0.00
Liabilities & Shareholder Equity
Accounts Payable	0,0.00
Short Term Debt	0,0.00
Total Current Liabilities	0,0.00
Long Term Debt	0,0.00
Deferred Income Taxes	0,0.00
Other Non-Current Liabilities	0,0.00
Minority Interest	0,0.00
Total Non-Current Liabilities	0,0.00
Preferred Stock Equity	0,0.00
Common Stock Equity	0,0.00
Common Par	0,0.00
Additional Paid In Capital	0,0.00
Cumulative Translation Adjustment	0,0.00
Retained Earnings	0,0.00
Treasury Stock	0,0.00
Other Equity Adjustments	0,0.00
Total Capitalization	0,0.00
TOTAL EQUITY	0,0.00
TOTAL LIABILITIES & STOCK EQUITY	0,0.00
Total Common Shares Outstanding	0,0.00
Preferred Shares	0,0.00
Treasury Shares	0,0.00
Basic Weighted Shares Outstanding	0,0.00
Diluted Weighted Shares Outstanding	0,0.00
Number Of Employees	0,0.00
Number Of Part-Time Employees	0,0.00

Select Period

TOTAL REVENUES	EBT Excluding Unusual Items	NET INCOME

Income Statement

	M Y
Sales	0,0.00
Cost Of Sales	0,0.00
Gross Operating Profit	0,0.00
Selling, General, And Administrative Expenses	0,0.00
Research & Development	0,0.00
Operating Income Before D & A (EBITDA)	0,0.00
Depreciation & Amortization	0,0.00
Interest Income	0,0.00
Other Income - Net	0,0.00
Special Income / Charges	0,0.00
Total Income Before Interest Expenses (EBIT)	0,0.00
Interest Expense	0,0.00
Pre-Tax Income	0,0.00
Income Taxes	0,0.00
Minority Interest	0,0.00
Net Income From Continuing Operations	0,0.00
Net Income From Discontinued Operations	0,0.00
Net Income From Total Operations	0,0.00
Extraordinary Income/Losses	0,0.00
Income From Cum. Effect Of Acct. Change	0,0.00
Income From Tax Loss Carryforward	0,0.00
Other Gains / Losses	0,0.00
Total Net Income	0,0.00
Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge)	0,0.00
Preferred Dividends	0,0.00
Net Income Available To Common	0,0.00
Basic EPS From Continuing Ops.	0,0.00
Basic EPS From Discontinued Ops.	0,0.00
Basic EPS From Total Operations	0,0.00
Basic EPS From Extraordinary Inc.	0,0.00
Basic EPS From Cum Effect Of Accounting Change	0,0.00
Basic EPS From Tax Loss Carryf'd.	0,0.00
Basic EPS From Other Gains (Losses)	0,0.00
Basic EPS, Total	0,0.00
Basic Normalized Net Income/Share	0,0.00
EPS From Continuing Ops.	0,0.00
EPS From Discontinued Ops	0,0.00
EPS From Total Ops.	0,0.00
EPS From Extraord. Inc.	0,0.00
EPS From Cum Effect of Accounting Change	0,0.00
EPS From Tax Loss Carfd.	0,0.00
EPS From Other Gains (L)	0,0.00
EPS, Total	0,0.00
Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge)	0,0.00
Dividends Paid Per Share	0,0.00

Select Period

CASH FROM OPERATIONS	CASH FROM INVESTING ACTIVITIES	CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

	M Y
Cash Flow From Operating Activities
Net Income (Loss)	0,0.00
Operating Gains/Losses	0,0.00
Gross Operating Profit	0,0.00
(Increase) Decrease In Receivables	0,0.00
(Increase) Decrease In Inventories	0,0.00
(Increase) Decrease In Other Current Assets	0,0.00
(Decrease) Increase In Other Current Liabilities	0,0.00
(Increase) Decrease In Other Working Capital	0,0.00
Other Non-Cash Items	0,0.00
Net Cash From Continuing Operations	0,0.00
Net Cash From Discontinued Operations	0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities	0,0.00
Sale Of Property, Plant & Equipment	0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments	0,0.00
Purchases Of Property, Plant & Equipment	0,0.00
Acquisitions	0,0.00
Purchases Of Short-Term Investments	0,0.00
Other Cash From Investing Activities	0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities	0,0.00
Issuance Of Debt	0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock	0,0.00
Repayment Of Long-Term Debt	0,0.00
Repurchase Of Capital Stock	0,0.00
Payment Of Cash Dividends	0,0.00
Other Financing Charges, Net	0,0.00
Net Cash From Financing Activities	0,0.00
Effect Of Exchange Rate Changes	0,0.00
Net Change In Cash & Cash Equivalents	0,0.00

Earnings Estimates

as of 4:00 ET PM 01/20/2022

	Current Qtr (12/2021)	Next Qtr (03/2022)
Consensus Estimate	$-0.88	$-0.75
# of Estimates	10	5
High Estimate	$-0.63	$-0.58
Low Estimate	$-1.11	$-0.94
Year Ago EPS	$-1.24	$-1.08
Year Over Year Growth Estimate	-29.16%	-30.35%

	Current Yr (12/2021)	Next Yr (12/2022)
Consensus Estimate	$-3.21	$-3.01
# of Estimates	6	10
High Estimate	$-2.94	$-2.50
Low Estimate	$-3.40	$-3.87
Year Ago EPS	$-3.86	$-3.21
Year Over Year Growth Estimate	-16.84%	-6.37%

	Current Qtr (12/2021)	Next Qtr (03/2022)	Current Year (12/2021)	Next Year (12/2022)
Consensus Estimate	$-0.88	$-0.75	$-3.21	$-3.01
# of Estimates	10	5	6	10
High Estimate	$-0.63	$-0.58	$-2.94	$-2.50
Low Estimate	$-1.11	$-0.94	$-3.40	$-3.87
Year Ago EPS	$-1.24	$-1.08	$-3.86	$-3.21
Year Over Year Growth Estimate	-29.16%	-30.35%	-16.84%	-6.37%